G Harrison

6.1k citations
30 papers · 4.6k indexed · 2 hit papers · h-index 19

Impact in

  • Hematology top 0.1%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 0.5%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Chronic Lymphocytic Leukemia Research

Papers in

G Harrison

30 papers receiving 4.5k citations

Hit Papers

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials 2001 · 1.2k citations
1.2k199820262007201650010001.5k2.0k

Peers

G Harrison
Comparison fields: 5 of 76
  • Hematology 4.0k
  • Genetics 1.0k
  • Public Health, Environmental and Occupational Health 1.9k
  • Molecular Biology 1.7k
  • Oncology 543
Replace FG Behm with:
FG Behm United States
MM Le Beau United States
F G Behm United States
Lewis R. Silverman United States
Diane C. Arthur United States
Preben Philip Denmark
Susanne Viehmann Germany
Jan Trka Czechia
DJ Pullen United States
Richard Ratei Germany
G Harrison relative to FG Behm United States FG Behm's profile →
Citations per field
00.5×4.9×
FG Behm · 1×
Citations per year

Countries citing papers authored by G Harrison

Since Specialization
Citations

This map shows the geographic impact of G Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Harrison more than expected).

Fields of papers citing papers by G Harrison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Harrison. The network helps show where G Harrison may publish in the future.

Co-authorship network

The 25 scholars most cited alongside G Harrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with G Harrison Line = papers co-authored together G Harrison links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Impact of karyotype on treatment outcome in acute myeloid leukemia.
200417
2 200327
3
Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.
20024
4 200218
5 200272
6 200230
7
Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993)
200121
8
Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
200121
9
Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit
20012
10 200142
11
Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12.
20002
12
The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.
20007
13 200028
14
Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
19998
15
Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
19991
16 199993
17 199983
18
The role of molecular diagnosis & residual disease monitoring in APL: Results of the MRC ATRA trial
19982
19 1997176
20
Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
19966

About G Harrison

G Harrison is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Genetics, Pediatrics, Perinatology and Child Health and Neurology, having authored 30 papers that have together received 4.6k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (23 papers), Acute Myeloid Leukemia Research (17 papers), Chronic Myeloid Leukemia Treatments (7 papers), Childhood Cancer Survivors' Quality of Life (6 papers), Hematopoietic Stem Cell Transplantation (5 papers), Retinoids in leukemia and cellular processes (3 papers), Neuroblastoma Research and Treatments (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Hematology (4.0k citations), Genetics (1.0k citations), Public Health, Environmental and Occupational Health (1.9k citations), Molecular Biology (1.7k citations) and Oncology (543 citations). G Harrison has collaborated with scholars based in United Kingdom, United States and India. Frequent co-authors include Keith Wheatley, Alan K. Burnett, Helen M. Walker, Ian Hann, Richard Stevens, John Rees, Christine J. Harrison, David Grimwade, Anthony P. Goldstone and Fiona Oliver. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia, Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026